Drugs / INCB086550
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05101369 | Jan → Mar 2022 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04674748 | Feb 2021 → May 2022 | cancer | Incyte Biosciences Japan GK | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03762447 | Dec 2018 → Nov 2023 | cancer | Incyte Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04629339 | Sep 2021 → Mar 2024 | hepatocellular carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB086550 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629339 ↗ |
| Action | Inhibit | “a potent small-molecule inhibitor of PD-L1, INCB086550” PMID 35254416 ↗ Jun 2022 |
| Modality | Small molecule | “a novel, oral, small-molecule PD-L1 inhibitor” PMID 35254416 ↗ Jun 2022 |
| Route | Oral | “INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.” NCT03762447 ↗ |